Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 50Prostatic Neoplasms 23Lung Neoplasms 17Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 13Neoplasms 9Stomach Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 5Endometrial Neoplasms 5Carcinoma, Squamous Cell 5Prostatic Neoplasms, Castration-Resistant 4Oropharyngeal Neoplasms 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3HER2-positive Breast Cancer 3Esophageal Squamous Cell Carcinoma 3Carcinoma 3Anatomic Stage I Breast Cancer AJCC v8 3Adenocarcinoma 3Vaccinia 2Solid Tumors 2Sarcoma 2Salivary Gland Neoplasms 2

Interventions

darolutamide 2Docetaxel 2Androgen Antagonists 2niraparib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × Docetaxel × 90 days × Clear all
NCT06661122 2026-05-19

HAYATE

Bayer

Recruiting
100 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06392841 2026-04-08

HARMONY

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡